Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference
Pieris Pharmaceuticals (NASDAQ:PIRS) announced that CEO Stephen S. Yoder will participate in a GI Oncology and Pancreatic Cancer panel at the Cowen 41st Annual Healthcare Conference on March 2, 2021, at 9:50 AM EST. Pieris focuses on developing innovative biotherapeutics using its proprietary Anticalin® technology for various diseases, including respiratory conditions and cancer. The company aims to advance its pipeline of inhalable therapies and immuno-oncology treatments. For more details, visit www.pieris.com.
- None.
- None.
BOSTON, MA / ACCESSWIRE / February 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that Stephen S. Yoder, President and Chief Executive Officer of Pieris, is scheduled to participate in a GI Oncology and Pancreatic Cancer panel discussion at the Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021 at 9:50 AM EST.
About Pieris Pharmaceuticals:
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.
Forward Looking Statement:
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the expected closing of the private placement; the expected timing and potential outcomes of the reporting by the Company of key clinical data from its lead programs, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data or making IND filings related to our programs, and partnering and funding prospects for any such programs. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to satisfy the closing conditions for the private placement; our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate; the timing and nature of data from the Phase 2a study of PRS-060/AZD1402; whether or not Pieris opts-into co-development of PRS-060/AZD1402; whether or not any of the warrants to be issued in the private placement will be exercised for cash; the use of any proceeds from any warrant exercise; and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and the Company's Quarterly Reports on Form 10-Q.
Investor Relations Contact:
Pieris Pharmaceuticals, Inc.
Maria Kelman
Director of Investor Relations
+1 857 362 9635
kelman@pieris.com
SOURCE: Pieris Pharmaceuticals, Inc.
View source version on accesswire.com:
https://www.accesswire.com/631166/Pieris-Pharmaceuticals-to-Participate-in-the-Cowen-41st-Annual-Health-Care-Conference
FAQ
What event will Pieris Pharmaceuticals participate in on March 2, 2021?
Who is representing Pieris Pharmaceuticals at the Cowen Healthcare Conference?
What is the focus of Pieris Pharmaceuticals' biotherapeutics?
What time is Pieris Pharmaceuticals' panel discussion scheduled for?
What is Anticalin technology?
Where can I find more information about Pieris Pharmaceuticals?
